Cargando…
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
Sulfatinib is a small molecule kinase inhibitor that targets tumor angiogenesis and immune modulation. This phase I study (NCT02133157) investigated the safety, pharmacokinetic characteristics, and preliminary anti-tumor activity of sulfatinib in patients with advanced solid tumors. The study includ...
Autores principales: | Xu, Jian Ming, Wang, Yan, Chen, Yu Ling, Jia, Ru, Li, Jie, Gong, Ji Fang, Li, Jing, Qi, Chuan, Hua, Ye, Tan, Cui Rong, Wang, Jian, Li, Ke, Sai, Yang, Zhou, Feng, Ren, Yong Xin, Qing, Wei Guo, Jia, Hong, Su, Wei Guo, Shen, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522050/ https://www.ncbi.nlm.nih.gov/pubmed/28159938 http://dx.doi.org/10.18632/oncotarget.14942 |
Ejemplares similares
-
Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment
por: Liao, Song, et al.
Publicado: (2023) -
A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
por: Zhang, Jian, et al.
Publicado: (2014) -
Resolving nanostructure and chemistry of solid-electrolyte interphase on lithium anodes by depth-sensitive plasmon-enhanced Raman spectroscopy
por: Gu, Yu, et al.
Publicado: (2023) -
Solid-to-liquid phase transition in the dissolution of cytosolic misfolded-protein aggregates
por: Tomaszewski, Alexis, et al.
Publicado: (2023) -
Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S‐phase arrest and promoting apoptosis through CHK1 pathway
por: Wu, Fan, et al.
Publicado: (2015)